Markets:

Overview

News

Currencies

International

Treasuries

Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

1.620 +0.030 (+1.89%)

Streaming Delayed Price Updated: 12:47 PM EST, Nov 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Prelude Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 Next >

Prelude Therapeutics to Participate in Citizens Life Sciences Conference

May 01, 2025

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Prelude Announces Presentations at 2025 AACR Annual Meeting

April 25, 2025

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Top movers analysis one hour before the close of the markets on 2025-03-28: top gainers and losers in today's session. ↗

March 28, 2025

Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

12 Health Care Stocks Moving In Friday's Intraday Session ↗

March 28, 2025

Via Benzinga

Traders are paying attention to the gapping stocks in Friday's session. ↗

March 28, 2025

Let's have a look at what is happening on the US markets on Friday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

March 28, 2025

Via Benzinga

Why Braze Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗

March 28, 2025

Via Benzinga

Wondering what's happening in today's after-hours session? ↗

March 27, 2025

Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 27, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

March 14, 2025

Via Benzinga

Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025

March 10, 2025

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

March 05, 2025

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

February 11, 2025

Via Benzinga

Why Lattice Semiconductor Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

February 11, 2025

Via Benzinga

Stay updated with the stocks that are on the move in today's after-hours session. ↗

February 10, 2025

The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Via Chartmill

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

December 11, 2024

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

November 27, 2024

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 06, 2024

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

October 24, 2024

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

October 09, 2024

PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation plenary session presentation: October 24, 2024, 10:00 AM CEST (4:00 AM EST)

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

September 13, 2024

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

September 09, 2024

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

UBS Posts Upbeat Earnings, Joins Victoria's Secret, Performance Food Group, Kellanova And Other Big Stocks Moving Higher On Wednesday ↗

August 14, 2024

Via Benzinga

PRLD Stock Earnings: Prelude Therapeutics Misses EPS for Q2 2024 ↗

August 12, 2024

PRLD stock results show that Prelude Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Via InvestorPlace

Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

August 12, 2024

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

July 09, 2024

From Prelude Therapeutics, Incorporated

Via GlobeNewswire

Wall Street's Top 10 Stock Calls This Week - Saturday, June 22 ↗

June 22, 2024

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of June 17-21, 2024.

Via Talk Markets

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

June 03, 2024

From Prelude Therapeutics, Inc.

Via GlobeNewswire

Prelude Therapeutics to Participate in Citizens JMP Life Sciences Conference

May 09, 2024

From Prelude Therapeutics, Inc.

Via GlobeNewswire

PRLD Stock Earnings: Prelude Therapeutics Beats EPS for Q1 2024 ↗

May 07, 2024

PRLD stock results show that Prelude Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.